AptarGroup, Inc. (NYSE: ATR), a global leader in dosing, dispensing, and protection technologies for drug and consumer products, has announced the award of a contract from the U.S. Federal Government to further develop its ActivShield™ technology. This innovative solution enables the sterilization of medical devices and instruments without requiring a power source, making it suitable for diverse environments, including rural areas, military settings, and healthcare facilities with limited or no existing sterilization capabilities.
AptarGroup, Inc. (NYSE: ATR) has received a contract from the U.S. Federal Government to further develop its ActivShield™ technology, which sterilizes medical devices and instruments without needing a power source. This innovative solution is ideal for various environments, including rural areas, military settings, and healthcare facilities with limited sterilization capabilities.
ActivShield™ builds on Aptar CSP Technologies’ 20 years of material science expertise and its established 3-Phase Activ-Polymer™ platform. The technology uses a specially engineered Activ-Film™ material that emits a controlled amount of chlorine dioxide gas, allowing for the sterilization of a wide range of medical devices without the health risks associated with Ethylene Oxide (EtO).
“As a leader in pharma dosing and protection technologies, we’re proud to collaborate with the U.S. Government to enhance ActivShield™ for medical device sterilization, particularly in locations without power,” said Stephan B. Tanda, Aptar President and CEO.
The technology can be customized to meet specific device requirements and conditions. Its compact size and stability make it easy to stockpile, and all materials are manufactured in the United States.
ActivShield™ is positioned to address unmet sterilization needs in remote or emergency settings, potentially reducing infection risks from inadequately sterilized devices. It also offers an alternative to expensive and unsafe sterilization methods like EtO, which has faced scrutiny for toxic emissions.
For military applications, ActivShield™ can provide wounded service members with access to sterilized instruments during critical pre-hospitalization periods in forward environments.
John Belfance, president of Aptar CSP Technologies, remarked, “ActivShield™ represents a breakthrough in material science that could greatly enhance reliable instrument sterilization in challenging environments, ultimately saving lives. We appreciate the government’s recognition of this technology and are excited to bring it to the forefront of sterilization methods.”
The five-year contract is valued at approximately $4.8 million and is supported by the US Army Medical Research and Development Command.
About Aptar
Aptar is a global leader in dosing, dispensing, and protection technologies for drug and consumer products, serving various markets including pharmaceuticals, beauty, food, and personal care. Aptar CSP Technologies utilizes its active material science expertise to transform ideas into market opportunities, streamlining the product development process and enhancing consumer and patient experiences. The company offers comprehensive services from concept ideation to global production and regulatory support, ensuring expedited speed-to-market.
